ACRIVON THERAPEUTICS INC (ACRV) Stock Analyst Ratings
USA - NASDAQ:ACRV - US0048901096 - Common Stock
2.015 USD
+0.02 (+0.75%)
ChartMill assigns a Buy % Consensus number of 83% to ACRV. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 11.39. This target is 465.26% above the current price.
ACRV was analyzed by 15 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ACRV.
In the previous month the buy percentage consensus was at a similar level.
ACRV was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-16 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-05-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-26 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-03-26 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-03-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-31 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-11-14 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | Ladenburg Thalmann | Upgrade | Neutral -> Buy |
| 2024-09-16 | BMO Capital | Reiterate | Outperform -> Outperform |
| 2024-09-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | BMO Capital | Reiterate | Outperform -> Outperform |
| 2024-05-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-29 | Ladenburg Thalmann | Downgrade | Buy -> Neutral |
| 2024-04-26 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-04-25 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-04-25 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-04-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-05 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2024-04-01 | BMO Capital | Reiterate | Outperform -> Outperform |
| 2024-04-01 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-01 | JMP Securities | Initiate | Market Outperform |
| 2023-11-10 | BMO Capital | Maintains | Outperform -> Outperform |
| 2023-10-05 | Maxim Group | Initiate | Buy |
| 2023-09-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
ACRIVON THERAPEUTICS INC / ACRV FAQ
What do analysts expect the price target to be for ACRIVON THERAPEUTICS INC (ACRV)?
15 analysts have analysed ACRV and the average price target is 11.39 USD. This implies a price increase of 465.26% is expected in the next year compared to the current price of 2.015.
Can you provide the consensus rating for ACRIVON THERAPEUTICS INC stock?
The consensus rating for ACRIVON THERAPEUTICS INC (ACRV) is 82.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover ACRIVON THERAPEUTICS INC (ACRV) stock?
The number of analysts covering ACRIVON THERAPEUTICS INC (ACRV) is 15.